165 completed, 31 unknown, 7 recruiting, 4 not yet recruiting. 81 Phase 1, 54 Phase 4, 37 Phase 3, 25 Phase 2, 18 Not applicable.
Follow Rabeprazole: new trials by email Literature Review of Rabeprazole trials Research Report on Rabeprazole
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Assessing the Effect of a Proton Pump Inhibitor on the Pharmacokinetics of DZD8586 in Healthy Participants (TAI-SHAN21) DZD8586, Rabeprazole - Healthy | Phase 1 | Not yet recruiting | Dizal Pharmaceuticals | 26 | 2026-10-16 | 2026-10-22 |
| Efficacy And Safety of Bismuth-Tetracycline-Rabeprazole Triple For First-Line Eradication of Helicobacter Pylori Infection Bismuth, Bismuth quadruple therapy - Helicobatcer Pylori, First-Line Eradication | Not applicable | Not yet recruiting | Chih-An Shih, MD | 300 | 2026-09-01 | 2026-08-26 |
| A Study of RO7890597 in Healthy Adult Volunteers RO7890597, Placebo, Rabeprazole - Healthy Volunteers | Phase 1 | Recruiting | Genentech, Inc. | 139 | 2026-08-28 | 2026-10-16 |
| A Study on the Effect of Food and Proton Pump Inhibitor on the Pharmacokinetics of HMPL-760 Capsules HMPL-760, Rabeprazole and HMPL-760 - Healthy Participants | Phase 1 | Completed | Hutchmed | 24 | 2026-06-30 | 2026-09-18 |
| A Study to Learn How Different Forms of the Study Medicine Called PF-08049820 Are Absorbed and Eliminated in Healthy Adults PF-08049820, Rabeprazole - Healthy Adults, Healthy | Phase 1 | Completed | Pfizer | 24 | 2026-05-13 | 2026-10-01 |
| Effect of ZaStaprazan on Platelet Reactivity of Clopidogrel After PercuTaneous CoronAry InteRvention Zastaprazan, Rabeprazole - Chronic Coronary Syndrome | Phase 4 | Recruiting | Yonsei University | 100 | 2026-04-02 | 2026-04-24 |
| A Study to Evaluate the Effect of Food and Proton Pump Inhibitor on the Pharmacokinetics of ZN-A-1041 in Healthy Participants ZN-A-1041 Formulation 1, ZN-A-1041 Formulation 2, Rabeprazole - Healthy Volunteers | Phase 1 | Completed | Genentech, Inc. | 24 | 2025-11-21 | 2026-05-11 |
| A Study to Learn if a Medicine That Reduces Stomach Acid Affects the Blood Level of Study Medicine PF-08049820 in Healthy Chinese Adults. PF-08049820, Rabeprazole - Healthy Adults | Phase 1 | Completed | Pfizer | 18 | 2025-11-03 | 2026-09-09 |
| Efficacies of Bismuth-amoxicillin-vonoprazan Triple Therapy and Bismuth Quadruple Therapy vonoprazan, tripotassium dicitrate bismuthate, amoxicilline, rabeprazole, tripotassium dicitrate bismuthate, tetracycline, metronidazole - Helicobacter Pylori Infection | Not applicable | Recruiting | Kaohsiung Medical University | 552 | 2025-10-21 | 2026-01-22 |
| Prophylactic Proton Pump Inhibition for Esophageal Protection in Lung Radiation Therapy Experimental (Health Canada Approved Proton Pump Inhibitors) - Primary Lung Cancer, Non Small Cell Lung Cancer | Phase 2 | Not yet recruiting | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 58 | 2025-10-02 | 2025-07-22 |
| A Study to Evaluate the Effect of Food and a Proton Pump Inhibitor on the Pharmacokinetics of VRN110755 VRN110755, Rabeprazole - Healthy | Phase 1 | Completed | Voronoi, Inc | 25 | 2025-08-27 | 2026-05-08 |
| Evaluate the Effects of Famotidine or Rabeprazole on the PK of Nirogacestat Nirogacestat, Nirogacestat and Famotidine, Nirogacestat and Rabeprazole - Healthy | Phase 1 | Completed | SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany | 24 | 2025-08-21 | 2026-05-08 |
| A Clinical Trial of Anaprazole for Treating Reflux Esophagitis. Anaprazole + Rabeprazole placebo, Rabeprazole + Anaprazole placebo - Reflux Esophagitis (RE) | Phase 3 | Recruiting | Xuanzhu Biopharmaceutical Co., Ltd. | 500 | 2025-07-30 | 2025-09-29 |
| Comparing the Extent to Which Three Different Formulations of LY4100511 (DC-853) Are Made Available in the Body, Alone and in the Presence of a Drug That Reduces Stomach Acid LY4100511, Rabeprazole - Healthy Participants | Phase 1 | Terminated | Eli Lilly and Company | 1 | 2025-04-08 | 2026-09-09 |
| Modular Clinical Pharmacology Study to Evaluate the Drug-drug Interaction Potential and Relative Bioavailability of Saruparib Saruparib, Digoxin, Furosemide - Advanced Solid Malignancies | Phase 1 | Active not recruiting | AstraZeneca | 41 | 2025-03-25 | 2026-10-01 |
| Study to Evaluate Safety, Drug Levels, Food and Relative Bioavailability of BMS-986365 in Healthy Adult Male Participants BMS-986365, Rabeprazole - Healthy Participants | Phase 1 | Completed | Celgene | 102 | 2024-05-28 | 2025-03-06 |
| Clinical Study Aiming to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Administration of ZE50-0134 at 5 Dose Levels in Healthy Volunteers ZE50-0134 or placebo, Rabeprazole 20 mg, Itraconazole (200 mg) - Healthy | Phase 1 | Completed | Lomond Therapeutics Holdings, Inc. | 104 | 2024-05-21 | 2025-12-05 |
| Efficacy and Safety of Keverprazan-amoxicillin Dual Therapy for Helicobacter Pylori First-line Treatment Keverprazan 10 days, Keverprazan 14 days, Rabeprazole - Helicobacter Pylori | Phase 4 | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 414 | 2024-02-19 | 2025-08-14 |
| A Study to Assess the Potential for Gastric-pH Dependent Drug-Drug Interactions of BIIB122 With a Proton Pump Inhibitor in Healthy Participants BIIB122, Rabeprazole - Healthy Volunteer | Phase 1 | Completed | Biogen | 18 | 2024-02-12 | 2024-07-19 |
| A Clinical Trial to Evaluate MK-4208/Embibatinib in Healthy Adult Participants (MK-4208-001/Embibatinib-1014) Embibatinib, Rabeprazole, Midazolam - Healthy | Phase 1 | Completed | Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 196 | 2023-12-21 | 2026-10-22 |
Showing 20 of 216. Sign in to see all of them.
Gastroesophageal Reflux (52) · Heartburn (9) · Esophagitis, Peptic (8) · Duodenal Ulcer (7) · Stomach Ulcer (7) · Stomach Neoplasms (6) · Gastrointestinal Hemorrhage (4) · Helicobacter Infections (4) · Dyspepsia (3) · Gastrointestinal Diseases (3) · Neoplasms (3) · Amyotrophic Lateral Sclerosis (2) · Asthma (2) · Disease (2) · Esophageal Diseases (2)
Eisai Co., Ltd. (13) · Eisai Inc. (13) · Genentech, Inc. (10) · Pfizer (10) · National Taiwan University Hospital (8) · AstraZeneca (5) · Shanghai Zhongshan Hospital (5) · Haihe Biopharma Co., Ltd. (4) · Hutchmed (4) · Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (4) · GlaxoSmithKline (3) · Janssen Korea, Ltd., Korea (3) · Janssen Research & Development, LLC (3) · Kaohsiung Medical University (3) · Second Affiliated Hospital, Zhejiang University, School of Medicine (3)
United States (63) · China (35) · Taiwan (20) · Japan (18) · South Korea (16) · United Kingdom (10) · Canada (9) · Australia (8) · Germany (6) · France (5) · Belgium (4) · Bulgaria (4) · India (4) · Netherlands (4) · Egypt (3)
Taotao Liu, MD (5) · Yufang Lu (5) · Jyh-Chin Yang, M.D.Ph.D. (4) · Nobuyuki Sugisaki (4) · Guillermo Rossiter, MD (2) · James D Carlson, Pharm. D. (2)
PMID 21114792, PMID 23689261, PMID 38359854, PMID 38910891, PMID 15233698, PMID 17116123, PMID 17721405, PMID 18852068, PMID 19210493, PMID 20132153, PMID 20132154, PMID 21317257, PMID 21726257, PMID 22108775, PMID 23102518, PMID 23856153, PMID 23863328, PMID 23957383, PMID 23980906, PMID 24121146, PMID 25027286, PMID 25574111, PMID 26628445, PMID 27129014, PMID 27154174, PMID 27641510, PMID 28502925, PMID 29188387, PMID 29562147, PMID 30167954, PMID 30536154, PMID 31067538, PMID 31335741, PMID 32811427, PMID 34336894, PMID 34397042, PMID 35445718, PMID 36580650, PMID 36650673, PMID 36940437, PMID 37133673, PMID 37479526, PMID 37705327, PMID 37885233, PMID 38906695, PMID 39087871, PMID 39711068, PMID 39924352, PMID 40007457, PMID 40077903
2017 (4), 2015 (2), 2008 (1), 2018 (1), 2019 (1), 2023 (1)